Chemomab Therapeutics Ltd ADR CMMB

$1.43 +0.13 (10.00%)

Valuation

Market cap
9,419,000
Revenue TTM
$0
Net income TTM
$-9,000,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
42,000
Avg volume
120,196
Day's range
$1.30 – $1.44
Shares out
7,246,000
Stochastic %K
24%
Beta
0.75
Analysts
Strong Sell
Price target
$5.00

Price

Company profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating prima...

Show more

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 77 331 0156
Website
https://www.chemomab.com
Address
Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel

Latest news

Stocktwits

Zdxss1 Oct 3, 6:55 PM
$CMMB There is a fundamental misunderstanding of how companies are valued. A company generating profits and owning solid assets with a valuation of $10 million can be worth far more than a company with $150 million in assets that continues to report recurring losses while operating in a business where the technology gradually loses value and the underlying assets erode over time. In my view, that is exactly what is happening with Scipher. Future value is what ultimately determines today's valuation. As for the merger, I believe CMMB agreed to it in order to secure the emergency $10 million financing. I am convinced that CMMB's management is not truly supportive of this transaction and understands that, if it goes through, it could face significant shareholder opposition and potential legal challenges. The important question is this: when CMMB signed the merger agreement, did it leave itself a way out of the deal? I believe there may be an exit path available
1 replies
InvestorNOR Oct 3, 3:55 PM 0 replies
InvestorNOR Oct 3, 3:54 PM 0 replies
InvestorNOR Oct 3, 11:49 AM
$CMMB They took the easy route. Remember, Company C RETURNED to Chemomab to discuss partnership/aquisition/whatever after hearing the cost of running a trial on the first round. By then the board had many merger talks with Scipher and they took the easy route by being misled by an overpromise of $150M valuation for the new company.
0 replies
cayman777 Oct 3, 11:34 AM
$CMMB -The management/board failed in this regard and it appears to be a breach of their fiduciary responsibility to shareholders.
0 replies
InvestorNOR Oct 3, 11:16 AM
$CMMB This is why we should tell the board in Chemomab to go F themselves. "It is a clinical-stage monoclonal antibody with a fibro-inflammatory mechanism, a completed Phase 2, orphan designations, and a Phase 3 path agreed with the FDA in PSC. That is ahead of MTX-463, which had only finished Phase 1, and ahead of DJS-002 and the Scholar Rock programs, which were preclinical. It is in the same band as PRM-151 and filgotinib, which were Phase 2 assets when those deals were signed."
0 replies
InvestorNOR Oct 3, 10:41 AM
$CMMB I wrote a bigger piece here. https://x.com/TraderNorway/status/2106333235386912892
0 replies
InvestorNOR Oct 3, 10:23 AM
$CMMB Put it this way: If valuation is not atleast approximate to what is written in the S-4, you might as well print it out and use it as a toilet paper. PIPE and Chemomab can already now see the tape, and they SHOULD withdraw from the merger. Here comes the interesting part: Chemomab wants to. They are probably watching their legacy go up in smoke right now. An IP that is promising for several diseases, now being valued at $10M. Scipher however doesnt want to. They run a failed business, they have almost no revenue. Its dried out. They have nothing to build upon and grow the company. So what do we do? We over-promise to an ignorant board on a biotech company with a valuable IP and a future, get them to put their signature in, and we lock in a free way to remove ourselves from the shackles of private equity, get listed on the Nasdaq stock market, with free access to hedges and institutions that can inject money in our failing business. PIPE probably already told Seeto this is the only way
0 replies